Acta Pharmaceutica Sinica B

Scope & Guideline

Pioneering Innovations in Drug Development

Introduction

Immerse yourself in the scholarly insights of Acta Pharmaceutica Sinica B with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN2211-3835
PublisherINST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
Support Open AccessYes
CountryChina
TypeJournal
Converge2012, from 2014 to 2024
AbbreviationACTA PHARM SIN B / Acta Pharm. Sin. B
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressC/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST, BEIJING 100050, PEOPLES R CHINA

Aims and Scopes

Acta Pharmaceutica Sinica B is a leading journal that focuses on the intersection of pharmaceutical sciences and biotechnology, emphasizing innovative drug discovery, development, and delivery methods. The journal aims to publish high-quality research that advances the understanding of medicinal chemistry, pharmacology, and therapeutic applications.
  1. Drug Discovery and Development:
    The journal covers innovative approaches in drug discovery, including small molecules, biologics, and traditional medicines, emphasizing their mechanisms of action and therapeutic potential.
  2. Nanomedicine and Drug Delivery Systems:
    Significant focus on nanotechnology for drug delivery, exploring the design, synthesis, and application of nanocarriers to enhance therapeutic efficacy and reduce side effects.
  3. Pharmacology and Toxicology:
    Research on the pharmacokinetics, pharmacodynamics, and toxicological evaluations of new drugs, providing insights into their safety and efficacy profiles.
  4. Biotechnology and Molecular Biology:
    Studies that leverage biotechnological advancements, including CRISPR and gene editing, for therapeutic purposes, particularly in cancer and genetic diseases.
  5. Phytochemistry and Natural Products:
    Exploration of bioactive compounds from natural sources, including their pharmacological effects, mechanisms of action, and potential for drug development.
  6. Clinical Translational Research:
    Research that bridges laboratory findings with clinical applications, focusing on the development of new therapeutic strategies and improving patient outcomes.
Acta Pharmaceutica Sinica B has seen a surge in research themes that reflect the latest trends and advancements in pharmaceutical sciences. These emerging scopes indicate a shift towards innovative methodologies and therapeutic strategies.
  1. Immunotherapy and Checkpoint Inhibition:
    Research focusing on immunotherapy, especially combination therapies that enhance immune response against tumors, has gained significant traction, indicating a paradigm shift in cancer treatment.
  2. Nanomedicine Innovations:
    There is a growing trend in the development of novel nanomedicine platforms for targeted drug delivery, including stimuli-responsive systems that enhance therapeutic efficacy and minimize side effects.
  3. CRISPR and Gene Editing Technologies:
    The application of CRISPR and other gene-editing technologies in drug development and disease treatment has emerged as a prominent theme, highlighting the potential for genetic therapies.
  4. Microbiome Research:
    Studies exploring the role of the gut microbiome in drug metabolism and therapeutic responses are gaining importance, reflecting a broader interest in personalized medicine.
  5. Artificial Intelligence in Drug Discovery:
    The integration of AI and machine learning in drug discovery processes is becoming increasingly prevalent, showcasing efforts to improve efficiency and accuracy in identifying potential drug candidates.
  6. Sustainable and Green Chemistry:
    Research emphasizing sustainable practices in drug development, including the use of renewable resources and eco-friendly processes, is on the rise, aligning with global sustainability goals.

Declining or Waning

While Acta Pharmaceutica Sinica B continues to thrive in numerous research areas, certain themes have shown signs of declining interest or publication frequency. These waning scopes reflect shifts in research focus and the evolving landscape of pharmaceutical sciences.
  1. Traditional Drug Formulations:
    There has been a noticeable decline in studies focused on traditional drug formulations, as research shifts toward novel delivery systems and advanced drug formulations.
  2. Conventional Chemotherapy Approaches:
    The focus on conventional chemotherapy methods is waning in favor of targeted therapies and immunotherapies, indicating a shift toward more personalized medicine.
  3. Basic Pharmacognosy Studies:
    Research specifically centered on pharmacognosy without the application of modern techniques or translational potential has decreased, as the field moves towards integrating pharmacognosy with molecular biology.
  4. Single-Drug Therapy Studies:
    The decline in publications focusing solely on single-drug therapies suggests a growing interest in combination therapies and multi-target approaches to enhance treatment efficacy.

Similar Journals

Journal of Reports in Pharmaceutical Sciences

Empowering Researchers with Cutting-Edge Findings.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2322-1232Frequency: 2 issues/year

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

Journal of Research in Pharmacy

Exploring New Horizons in Pharmacy and Toxicology
Publisher: MARMARA UNIVISSN: 2630-6344Frequency: 4 issues/year

Journal of Research in Pharmacy, published by Marmara University, serves as a pivotal platform for the dissemination of innovative research in the field of pharmacology and pharmaceutical sciences. With an ISSN of 2630-6344 and an E-ISSN of the same, this journal is dedicated to publishing high-quality research spanning various aspects of pharmacology, toxicology, and pharmaceutics. The journal, categorized in Q3 for both pharmacology (medical) and miscellaneous pharmacology, toxicology, and pharmaceutics in 2023, showcases the ongoing evolution of these disciplines amid growing scientific inquiry. As of now, it ranks #56/80 in general pharmacology, toxicology and pharmaceutics, spotlighting its relevance within the academic community. Although it operates under a traditional access model, the journal is committed to providing researchers, professionals, and students with a comprehensive understanding of contemporary challenges and innovations in pharmacy research. Established in 2019, it continues to foster academic dialogue and contribute significantly to the advancement of pharmacological sciences until at least 2024. For all interested in cutting-edge pharmaceutical research, this journal presents an invaluable resource from its base in Istanbul, Turkey.

PHARMACEUTICAL CHEMISTRY JOURNAL

Empowering Researchers in Pharmaceutical Sciences.
Publisher: SPRINGERISSN: 0091-150XFrequency: 12 issues/year

Pharmaceutical Chemistry Journal is a pivotal publication in the field of pharmaceutical sciences, renowned for its in-depth articles and research findings. Published by Springer in the United States, this journal provides a crucial platform for researchers, students, and professionals dedicated to advancing drug discovery and pharmacology. With an ISSN of 0091-150X and an E-ISSN of 1573-9031, this journal has consistently aimed to promote scholarly communication and innovation within its scope since its inception in 1967. Despite its current Category Quartiles ranking of Q4 in both Drug Discovery and Pharmacology, the journal remains a valuable resource for disseminating new ideas and findings that contribute to the scientific community. Researchers benefit from the journal's commitment to high-quality peer-reviewed content, even in an environment where open access options are currently not available. As the field evolves, the Pharmaceutical Chemistry Journal continues to play an important role in shaping future advancements in drug development and safety.

Pakistan Journal of Pharmaceutical Sciences

Delivering critical studies that shape the pharmaceutical landscape.
Publisher: UNIV KARACHIISSN: 1011-601XFrequency: 4 issues/year

Pakistan Journal of Pharmaceutical Sciences, published by the University of Karachi, serves as a vital platform for advancing research in the field of pharmaceutical sciences. With a strong commitment to disseminating innovative findings and critical studies since its inception in 1995, the journal focuses on a wide array of topics including pharmacology, toxicology, and pharmaceutics. With an ISSN of 1011-601X, it holds a reputable position within the academic community, reflecting its Q3 category ranking in Pharmaceutical Science as of 2023. While the journal is currently not designated as Open Access, it remains accessible through institutional subscriptions, ensuring that both emerging and established researchers can contribute to and benefit from its scholarly content. This publication not only promotes scientific dialogue but also aims to bridge the gap between academia and industry, appealing to a diverse audience of researchers, professionals, and students seeking to stay informed about the latest advancements and trends in pharmaceutical research.

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Connecting Academia and Industry for Drug Discovery
Publisher: TAYLOR & FRANCIS LTDISSN: 0363-9045Frequency: 12 issues/year

Drug Development and Industrial Pharmacy is a prestigious journal published by Taylor & Francis Ltd, focusing on the critical field of pharmaceutical sciences. With an ISSN of 0363-9045 and an E-ISSN of 1520-5762, the journal has been an essential resource for researchers and professionals since its inception in 1974. It occupies a crucial niche within Drug Discovery, Organic Chemistry, and Pharmaceutical Science, currently ranked in the second and third quartiles, reflecting its solid contribution to the field. The journal encompasses a wide array of topics, including drug development processes, formulation, and industrial manufacturing alongside cutting-edge research in pharmacology and toxicology. With a commendable Scopus ranking demonstrating high relevance—ranked #44 in Pharmaceutical Science—it serves as a vital forum for academia and industry to share innovative findings and methodologies. While it does not offer open access, the journal remains an invaluable resource for those seeking to advance their knowledge and enhance their research in pharmaceutical development.

Research in Pharmaceutical Sciences

Exploring the Frontiers of Drug Development
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1735-5362Frequency: 6 issues/year

Research in Pharmaceutical Sciences is a premier, peer-reviewed journal published by Wolters Kluwer Medknow Publications, dedicated to advancing the field of pharmacology, toxicology, and pharmaceutics. With an impact factor that positions it in the second quartile of its category (Q2) and a respectable rank of 23 out of 80 in Scopus, this journal serves as an essential platform for researchers, professionals, and students alike, providing open access since 2015 to a wealth of pioneering studies and comprehensive reviews. Based in Mumbai, India, the journal encompasses a diverse range of topics within the pharmaceutical sciences, offering insights that address both theoretical and practical challenges in drug development and safety. As it converges from 2009 to 2024, Research in Pharmaceutical Sciences continues to be a vital source of knowledge, promoting innovation and fostering collaboration within the global scientific community.

International Journal of Pharmaceutical Investigation

Driving Innovation in Drug Development and Formulation
Publisher: INPHARM ASSOC, PHCOG NETISSN: 2230-973XFrequency: 4 issues/year

International Journal of Pharmaceutical Investigation, published by INPHARM ASSOC, PHCOG NET, is a premier platform dedicated to advancing the field of pharmaceutical sciences. With the ISSN 2230-973X and E-ISSN 2230-9713, this journal serves as a vital resource for researchers, professionals, and students focused on drug development, formulation, and efficacy. By fostering a rich discourse on innovative pharmaceutical practices and research breakthroughs, the journal plays a critical role in enhancing global health outcomes through groundbreaking scholarly work. The absence of open access allows for selective dissemination of high-quality content, promoting rigorous peer-review processes that uphold academic integrity. Featuring articles that span a diverse range of topics within pharmaceutical sciences, the International Journal of Pharmaceutical Investigation is committed to supporting the ongoing evolution of this dynamic field, making it an essential read for anyone engaged in pharmaceutical research and development.

YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN

Advancing pharmaceutical knowledge, one article at a time.
Publisher: PHARMACEUTICAL SOC JAPANISSN: 0031-6903Frequency: 12 issues/year

YAKUGAKU ZASSHI - JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, published by the Pharmaceutical Society of Japan, is a key academic journal dedicated to advancing the field of pharmaceutical sciences. Established in 1961 and set to contribute until 2024, this journal publishes original research articles, reviews, and clinical studies that encompass a wide spectrum of topics within pharmacology, toxicology, and pharmaceutics. Although the journal operates under a traditional subscription model, it maintains a recognized reputation with an impact factor that is steadily aligned within its category quartiles—ranking Q3 in Pharmaceutical Science and Q4 in Pharmacology as of 2023. With Scopus rankings reflecting its competitive standing, YAKUGAKU ZASSHI serves as a vital resource for researchers, professionals, and students looking to engage with innovative findings and broaden their understanding of pharmaceutical methodologies and research practices. With a current focus on bridging scientific research with real-world applications, it seeks to foster collaboration and knowledge sharing within the pharmaceutical community.

Ars Pharmaceutica

Pioneering research that shapes the future of pharmacy.
Publisher: UNIV GRANADA, EDITORIALISSN: 0004-2927Frequency: 4 issues/year

Ars Pharmaceutica is a distinguished open-access journal published by UNIV GRANADA, EDITORIAL, that has been at the forefront of pharmaceutical sciences since its establishment. With ISSN 0004-2927 and E-ISSN 2340-9894, this journal aims to disseminate high-quality research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of the field. With a historical scope that spans from 1980 to 2017, it has played a pivotal role in shaping the discourse surrounding pharmaceutical science and its intersection with the arts and humanities. Although currently ranked within the 13th percentile in Scopus for Pharmaceutical Science and the 11th percentile for History and Philosophy of Science, Ars Pharmaceutica continues to uphold its commitment to academic excellence and innovation. By providing a platform for open-access research, it encourages collaboration and knowledge sharing among researchers, professionals, and students, thus enhancing the broader understanding of pharmaceutical developments and their societal implications.

ADVANCED DRUG DELIVERY REVIEWS

Advancing Knowledge in Drug Delivery Systems.
Publisher: ELSEVIERISSN: 0169-409XFrequency: 12 issues/year

ADVANCED DRUG DELIVERY REVIEWS, published by ELSEVIER, is a leading journal in the field of pharmaceutical sciences, particularly acclaimed for its contributions to the disciplines of pharmacology, toxicology, and pharmaceutics. With an impressive 2023 Scopus rank of #1 out of 183 in its category, this journal is situated in the Q1 quartile, reflecting its high impact and the relevance of its published research. Since its inception in 1987, it has continually focused on the latest advancements in drug delivery systems, making it an indispensable resource for researchers, professionals, and students interested in the innovative developments that shape the pharmaceutical landscape. The journal aims to publish comprehensive and authoritative reviews that foster a deeper understanding of drug delivery mechanisms, technologies, and their clinical applications. Although it operates under a subscription model, the value it provides through rigorous peer-reviewed content ensures it remains an essential tool for anyone seeking to enhance their knowledge in this rapidly evolving field.